Rani Therapeutics at Chardan healthcare conference: platform gains traction

On October 20, 2026, Rani Therapeutics (RANI) showcased its oral biologics platform during Chardan’s 10th Annual Healthcare Conference. The technology allows large molecules to be delivered orally, similar to injection, but without the pain or safety concerns of needles. Management acknowledged challenges such as investor skepticism, larger studies needed, and proving economics at scale.

The company's swallowable RaniPill can deliver biologics, including monoclonal antibodies, proteins, peptides, and oligonucleotides, with bioavailability comparable to subcutaneous injection. Rani highlighted clinical data from RT-114, showing over 150% bioavailability versus matched 12 mg subcutaneous dosing, with no adverse events from the device.

The company has $53 million in cash and securities and expects to remain solvent through 2027, with potential upside from milestone payments. Its CEO, Talat Imran, described the platform as a solution to the challenge of delivering large molecules orally. Rani has completed four clinical studies with over 250 pills administered, seeing no injection-site reactions or device-related adverse events.

The lead obesity program with ProGen Therapeutics, RT-114, produced more than 150% bioavailability versus a matched 12 mg subcutaneous dose in 30 healthy volunteers. The company also has partnerships with Chugai and PegBio, with Chugai signing a $1.1 billion deal and PegBio providing access to multiple molecules in obesity and metabolic disease.